Related Experiment Video
Updated: Aug 9, 2026
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
Pulsatile insulin secretion in elderly patients with diabetes
Graydon S Meneilly1, Johannes D Veldhuis, Dariush Elahi
1The Division of Geriatric Medicine, the Department of Medicine, Room 3300-950 West 10th Ave., University of British Columbia, Vancouver, BC, Canada V5Z4E3.
Diabetes Research and Clinical Practice
|April 20, 2006
Summary
Glucagon-like peptide-1 (GLP-1) did not enhance pulsatile insulin secretion or alter glucose metabolism in elderly patients with type 2 diabetes. Further research is needed to understand insulin pulse effects.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Geriatric Medicine
Background:
- Insulin pulsation is crucial for glucose homeostasis but is impaired in type 2 diabetes.
- Glucagon-like peptide-1 (GLP-1) has shown potential in improving pulsatile insulin secretion in diabetic patients.
Purpose of the Study:
- To investigate the effect of GLP-1 on pulsatile insulin secretion and glucose metabolism in elderly patients with type 2 diabetes.
- To determine if GLP-1 can restore or enhance insulin pulsatility in this demographic.
Main Methods:
- Nine elderly patients with type 2 diabetes underwent three glucose clamp studies.
- GLP-1 infusion was administered, with one study including octreotide to suppress endogenous insulin pulsatility.
- 3-(3)H-glucose infusion was used to measure hepatic glucose production and glucose disposal rates.
Main Results:
- No significant differences were observed in pulsatile insulin secretion between the study conditions.
- Hepatic glucose production and glucose disposal rates remained unchanged despite GLP-1 administration.
- The study design did not allow for the assessment of pulsatile insulin's effect on glucose metabolism due to lack of difference in pulsatility.
Conclusions:
- GLP-1 did not significantly affect pulsatile insulin secretion or glucose metabolism in elderly type 2 diabetes patients under the tested conditions.
- Further investigation is required to elucidate the role of insulin pulses in glucose metabolism and the potential therapeutic effects of GLP-1.
- The study highlights the complexity of insulin secretion dynamics and glucose regulation in older adults with diabetes.
Related Concept Videos
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:05Insulin Secretory Vesicles
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...